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apy was evidently higher than the group of after two cycle chemo-
therapy. Nevertheless,there was no statistically signiﬁcant difference 
between two groups(P=0.063).
Conclusion: Effective chemotherapy may decrease the chance of 
micrometastasis.But it need to further proved.
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Background: Cisplatin is the most widely used agent in the chemo-
therapy of non-small cell lung cancer. In tumor cells, excision repair 
cross complement 1 (ERCC1) blocks the effect of cisplatin by repairing 
the cisplatin-DNA adduct, so the expression of ERCC1 in the tumor 
cells could be a predictor of response to chemotherapy. But the signiﬁ-
cance of the expression in the normal lung tissue is not well known. 
In this study, the levels of ERCC1 expression in the tumor tissue and 
normal tissue were compared.
Materials and Methods: The level of ERCC1 was measured in the 
tumor tissue from the surgical specimens of 28 patients with non-small 
cell lung cancer, using the real-time RT-PCR. In 13 patients, the expres-
sion of ERCC1 was measured in both the normal and the tumor tissues 
simultaneously. The ERCC1 levels of normal tissues and tumor tissues 
were also analysed according to the patients’ characteristics. The level 
was expressed as a percentage value compared to that of the A549 lung 
cancer cell line. 
Result: The mean level of ERCC1 expressions in 28 tumor tissues was 
signiﬁcantly higher than that in the normal tissues (192.9 % (0 - 1460.1 
%) vs. 8.2 % (0 to 28.2 %)). In the 13 cases, in which ERCC1 was mea-
sured simultaneously, ERCC1 was more increased in the tumor tissues 
except in two cases, but the differences were not signiﬁcant(p=0.233). 
When the upper limit of ERCC1 expression in the normal tissues (30 
%) was used as the cut-off level, 13 cases (46 %) expressed more than 
30 %. The differences of ERCC1 expression in the tumor tissues by the 
age, sex, smoking, CEA level, pathologic stages, T stages, N stages and 
cell types were not signiﬁcant. But some tendency of increased expres-
sion of ERCC1 was observed in the groups with higher T stages and 
adenocarcinoma histology. 
Conclusion: The expression of ERCC1 was higher in the tumor tissue 
than the normal tissue. However, the difference was insigniﬁcant. In 46 
% of the tumor tissues, ERCC1 was expressed above the highest level 
of the normal tissues. 
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Background: Tumor markers have not been generally recommended 
as a tool for the detection of lung cancer, because of the low speciﬁcity 
and sensitivity. Several reports have suggested the use of a combination 
of tumor markers in the follow-up of lung cancer patients, although 
the most useful combination remains subject to discussion. Here, using 
stepwise logistic regression analysis, the most useful combination with 
multiple serum tumor markers was examined for a prediction model in 
non-small cell lung cancer diagnosis.
Methods: We retrospectively reviewed our medical records of patients 
who had pre-operative measurements for seven serum tumor markers; 
carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-
9), cytokeratin 19-fragments (CYFRA 21-1), sialyl Lewis X-i antigen 
(SLX), Squamous cell carcinoma antigen (SCC), neuron speciﬁc 
enolase (NSE), pro-gastrin-releasing peptide (ProGRP). We conducted 
90 patients with non-small cell lung cancers and 10 with non-cancers 
who performed surgery for diagnosis or treatment in our department at 
Kansai Medical University Hospital from March 2004 to April 2005. 
Upper cutoff levels routinely used in our institution for CEA, CA19-9, 
CYFRA 21-1, SLX, SCC, NSE, ProGRP were 5 ng/ml, 37 ng/ml, and 
3.5 ng/ml, 38 ng/ml, 1.5 ng/ml, 10 ng/ml, 46 ng/ml, respectively. The 
prediction power for the diagnosis of lung cancer was evaluated by uni-
variate logistic regression analysis to calculate odds ratios, 95 percent 
conﬁdence intervals and area under receiver-operating characteristics 
(ROC) curves, using JMP version 5.1. Stepwise analysis was then used 
to select and identify the most important independent predictors of lung 
cancer. To strengthen the prediction model with the serum tumor mark-
ers selected by the stepwise analysis, we additionally collected data 
for 50 patients with lung cancers and 8 patients who were suspected to 
have lung cancers, but then appeared to have non-cancer nodules by 
pathological ﬁndings with surgical biopsies. The selected serum tumor 
markers, with totally 140 patients with lung cancers and 18 patients 
with non-cancer nodules, revised the prediction model for lung cancer 
diagnosis.
Results: Two of seven tumor markers; CEA, CYFRA 21-1, had statisti-
cal signiﬁcance in univariate analysis for prediction of lung cancer 
diagnosis (P-value; 0.0068 and 0.0012, respectively). The odds ratios 
were both signiﬁcantly high. Area under ROC curve were 0.79 and 
0.87, respectively. A stepwise logistic regression for lung cancer diag-
nosis using the seven serum tumor markers demonstrated that a model 
containing CEA and CYFRA 21-1 was the most predictive (P<0.0001, 
area under ROC curve; 0.91). Revised prediction model using CEA and 
CYFRA 21-1 with total 158 cases including additional 50 lung cancers 
and 8 non-cancer nodules showed statistical signiﬁcance (area under 
ROC curve; 0.85). Using the revised model with CEA and CYFRA 
21-1, a cut-off value for lung cancer diagnosis showed that sensitivity 
was 0.7 and speciﬁcity was 0.94, although 47 % of CEA and 74 % of 
CYFRA 21-1 were negative.
Conclusions: Prediction model with multiple serum tumor markers is 
potentially useful for lung cancer diagnosis. CEA and CYFRA 21-1 
were the candidates to develop the prediction model in non-small cell 
lung cancer.
